Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9154468 | American Heart Journal | 2005 | 9 Pages |
Abstract
In ELITE II, the effects of losartan on HF-related outcomes, NYHA class, and QoL were not superior to those of captopril. Although angiotensin-converting enzyme inhibitors remain the treatment of choice for patients with HF, the similarity of the findings in the present analysis supports a role for angiotensin-receptor antagonists in this patient population.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Marvin A. MD, James D. PhD, Philip A. MD, Bertram MD, Robert MD, Divakar PhD, Erik J. PhD, George W. PhD, Kenneth MD, Günter MD, A. John MD, Felipe A. MD, Deborah C. BS, Leila S. BA, Emanuela P. MS,